Indoco Remedies Ltd
24 Oct 2024 12:00 AM
Indoco Remedies reports consolidated net loss of Rs 9.57 crore in the September 2024 quarter,
Net loss of Indoco Remedies reported to Rs 9.57 crore in the quarter ended September 2024 as against net profit of Rs 35.08 crore during the previous quarter ended September 2023. Sales declined 9.06% to Rs 430.66 crore in the quarter ended September 2024 as against Rs 473.58 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales430.66473.58 -9 OPM %9.3515.07 - PBDT23.9867.69 -65 PBT-4.8446.28 PL NP-9.5735.08 PL Powered by Capital Market - Live News
Indoco Remedies Ltd
15 Oct 2024 12:00 AM
Indoco Remedies to convene board meeting,
Indoco Remedies will hold a meeting of the Board of Directors of the Company on 24 October 2024.Powered by Capital Market - Live News
Indoco Remedies Ltd
11 Oct 2024 12:00 AM
Indoco Remedies update on USFDA inspection of its facilities in Goa,
Indoco Remedies has received regulatory status from U.S. Food and Drug Administration (USFDA), for its facilities located at Goa Plant-II & III, L-32,33,34, Verna Industrial Area, Verna, Goa, Goa 403722, India (Facility), following an inspection conducted by USFDA in July 2024. The USFDA has determined that the inspection classification of this Facility remains as `Official Action Indicated` (OAI). The Facility had been inspected by the USFDA in February 2023 and had received an OAI status in May 2023. Indoco is comprehensively working on the remedial action plan at the Facility which will be completed by Q3 2024. Indoco had planned to inform USFDA for the inspection readiness post completion of the remedial action. However, USFDA had visited the Facility in July 2024, while the remedial action was still in progress. Hence, the compliance status of the Facility received as `OAI` dated 10th October 2024, remains the samePowered by Capital Market - Live News
Indoco Remedies Ltd
04 Oct 2024 12:00 AM
Indoco Remedies receives USFDA approval for Cetirizine Hydrochloride Tablets,
Indoco Remedies (Indoco) announced the receipt of final approval from the USFDA for Abbreviated New Drug Application (ANDA) for Cetirizine Hydrochloride Tablets USP, 10 mg (OTC), a generic equivalent of the Reference Listed Drug, Zyrtec Allergy Tablets, 10 mg of Johnson & Johnson Consumer Inc. Cetirizine Hydrochloride Tablets USP, 10 mg will be manufactured by Indoco, at their manufacturing facility located at L-14, Verna Industrial Area, Verna, Goa - 403722 in India. Cetirizine is used for relief of symptoms of hay fever and other allergic conditions.Powered by Capital Market - Live News
Indoco Remedies Ltd
31 Aug 2024 12:00 AM
Indoco Remedies AGM scheduled,
Indoco Remedies announced that the Annual General Meeting (AGM) of the company will be held on 26 September 2024.Powered by Capital Market - Live News
Subscribe for our
newsletter
newsletter